Literature DB >> 24273176

Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission.

Elijah Paintsil1, Mawuena Binka, Amisha Patel, Brett D Lindenbach, Robert Heimer.   

Abstract

BACKGROUND: Healthcare workers may come into contact with fomites that contain infectious hepatitis C virus (HCV) during preparation of plasma or following placement or removal of venous lines. Similarly, injection drugs users may come into contact with fomites. Hypothesizing that prolonged viability of HCV in fomites may contribute significantly to incidence, we determined the longevity of virus infectivity and the effectiveness of antiseptics.
METHODS: We determined the volume of drops misplaced during transfer of serum or plasma. Aliquots equivalent to the maximum drop volume of plasma spiked with the 2a HCV reporter virus were loaded into 24-well plates. Plates were stored uncovered at 3 temperatures: 4°C, 22°C, and 37°C for up to 6 weeks before viral infectivity was determined in a microculture assay.
RESULTS: The mean volume of an accidental drop was 29 µL (min-max of 20-33 µL). At storage temperatures 4°C and 22°C, we recovered viable HCV from the low-titer spots for up to 6 weeks of storage. The rank order of HCV virucidal activity of commonly used antiseptics was bleach (1:10) > cavicide (1:10) > ethanol (70%).
CONCLUSIONS: The hypothesis of potential transmission from fomites was supported by the experimental results. The anti-HCV activity of commercial antiseptics varied.

Entities:  

Keywords:  fomites; hepatitis C virus; infectivity; nosocomial; transmission; virucidal agents

Mesh:

Year:  2013        PMID: 24273176      PMCID: PMC3969546          DOI: 10.1093/infdis/jit648

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

1.  A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany.

Authors:  K Stark; U Herrmann; S Ehrhardt; U Bienzle
Journal:  Epidemiol Infect       Date:  2005-12-22       Impact factor: 2.451

2.  Hospital admission is a relevant source of hepatitis C virus acquisition in Spain.

Authors:  Eva Martínez-Bauer; Xavier Forns; Mercé Armelles; Ramon Planas; Ricard Solà; Mercé Vergara; Silvia Fàbregas; Roser Vega; Javier Salmerón; Moisés Diago; Jose María Sánchez-Tapias; Miquel Bruguera
Journal:  J Hepatol       Date:  2007-10-12       Impact factor: 25.083

3.  Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care?

Authors:  Katja Deterding; Johannes Wiegand; Norbert Grüner; Heiner Wedemeyer
Journal:  J Hepatol       Date:  2008-03-31       Impact factor: 25.083

4.  Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001.

Authors:  Don C Des Jarlais; Theresa Perlis; Kamyar Arasteh; Lucia V Torian; Holly Hagan; Sara Beatrice; Lou Smith; Judith Wethers; Judith Milliken; Donna Mildvan; Stanley Yancovitz; Samuel R Friedman
Journal:  AIDS       Date:  2005-10       Impact factor: 4.177

5.  Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.

Authors:  Lisa Maher; Bin Jalaludin; Kerry G Chant; Rohan Jayasuriya; Tim Sladden; John M Kaldor; Penny L Sargent
Journal:  Addiction       Date:  2006-10       Impact factor: 6.526

6.  Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy.

Authors:  T Santantonio; E Medda; C Ferrari; P Fabris; G Cariti; M Massari; S Babudieri; M Toti; R Francavilla; F Ancarani; G Antonucci; G Scotto; V Di Marco; G Pastore; T Stroffolini
Journal:  Clin Infect Dis       Date:  2006-09-27       Impact factor: 9.079

7.  Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection.

Authors:  Elijah Paintsil; Sergei V Verevochkin; Elena Dukhovlinova; Linda Niccolai; Russell Barbour; Edward White; Olga V Toussova; Louis Alexander; Andrei P Kozlov; Robert Heimer
Journal:  Addiction       Date:  2009-08-27       Impact factor: 6.526

8.  Infectivity of hepatitis C virus in plasma after drying and storing at room temperature.

Authors:  Saleem Kamili; Kris Krawczynski; Karen McCaustland; Xiaofang Li; Miriam J Alter
Journal:  Infect Control Hosp Epidemiol       Date:  2007-04-16       Impact factor: 3.254

9.  The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004.

Authors:  Deborah Holtzman; Vaughn Barry; Lawrence J Ouellet; Don C Des Jarlais; David Vlahov; Elizabeth T Golub; Sharon M Hudson; Richard S Garfein
Journal:  Prev Med       Date:  2009-05-04       Impact factor: 4.018

10.  Complete replication of hepatitis C virus in cell culture.

Authors:  Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice
Journal:  Science       Date:  2005-06-09       Impact factor: 47.728

View more
  34 in total

Review 1.  Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C.

Authors:  Asher J Schranz; Jessica Barrett; Christopher B Hurt; Carlos Malvestutto; William C Miller
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

2.  Hepatitis C virus infection: from margin to center in rhode island and beyond.

Authors:  Lynn E Taylor
Journal:  R I Med J (2013)       Date:  2014-07-01

3.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

4.  Hepatitis A and Hepatitis B Vaccination Coverage Among Persons Who Inject Drugs and Have Evidence of Hepatitis C Infection.

Authors:  Ruth Koepke; Danielle N Sill; Wajiha Z Akhtar; Kailynn P Mitchell; Sheila M Guilfoyle; Ryan P Westergaard; Stephanie L Schauer; James M Vergeront
Journal:  Public Health Rep       Date:  2019-09-20       Impact factor: 2.792

5.  Transmission of blood-borne pathogens in US dental health care settings: 2016 update.

Authors:  Jennifer L Cleveland; Shellie Kolavic Gray; Jennifer A Harte; Valerie A Robison; Anne C Moorman; Barbara F Gooch
Journal:  J Am Dent Assoc       Date:  2016-05-24       Impact factor: 3.634

6.  Mechanisms of methods for hepatitis C virus inactivation.

Authors:  Stephanie Pfaender; Janine Brinkmann; Daniel Todt; Nina Riebesehl; Joerg Steinmann; Jochen Steinmann; Thomas Pietschmann; Eike Steinmann
Journal:  Appl Environ Microbiol       Date:  2014-12-19       Impact factor: 4.792

7.  Hepatitis C in Canada and the importance of risk-based screening.

Authors:  S Ha; S Totten; L Pogany; J Wu; M Gale-Rowe
Journal:  Can Commun Dis Rep       Date:  2016-03-03

8.  Recovery of Infectious Hepatitis C Virus From Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs.

Authors:  Robert Heimer; Mawuena Binka; Stephen Koester; Jean-Paul C Grund; Amisha Patel; Elijah Paintsil; Brett D Lindenbach
Journal:  J Infect Dis       Date:  2018-01-17       Impact factor: 5.226

9.  Association between alcohol consumption and injection and sexual risk behaviors among people who inject drugs in rural Puerto Rico.

Authors:  Melissa Welch-Lazoritz; Dane Hautala; Patrick Habecker; Kirk Dombrowski
Journal:  J Subst Abuse Treat       Date:  2017-08-10

10.  Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users.

Authors:  Marian Major; Alexander Gutfraind; Louis Shekhtman; Qingwen Cui; Alla Kachko; Scott J Cotler; Behzad Hajarizadeh; Rachel Sacks-Davis; Kimberly Page; Basmattee Boodram; Harel Dahari
Journal:  Sci Transl Med       Date:  2018-07-11       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.